title: Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
abstract: The primary objective of Safety Pharmacology is to ensure the safety of medicines on physiological functions in order to protect humans against adverse drug reactions. Safety Pharmacology became a major non-clinical discipline in 2000 when the International Conference on Harmonization approved the S7A guideline. This regulatory document requires pharmaceutical companies to undertake Safety Pharmacology assessment under Good Laboratory Practice (GLP) in order to guarantee the absence of unmanageable risks on vital organ function for compounds to be tested on humans. These regulatory studies often reveal liabilities impacting on the smooth transition of drug candidates from the discovery phase into the clinical arena. However, if these safety issues were uncovered prior to regulatory science assessment, the chemistry of poorly safe molecules could be modified during the lead optimisation phase for preventing later occurring attrition accidents. This article proposes the establishment of a spin-off specialty of Regulatory Safety Pharmacology, for which the name 'Exploratory Safety Pharmacology' is proposed. The objective of this discipline would be to conduct early safety investigations on potential drug candidates by applying, outside the constraints of GLP, in silico, in vitro, ex vivo and in vivo platforms translating clinical liabilities into simple, fast and cost-effective screening assays. This approach should result in early hazard detection with rapid turnaround of the data, enabling medicinal chemists to mitigate the safety liabilities of new compounds in an iterative manner. Hence, the ultimate aim of Exploratory Safety Pharmacology activities is to transform Regulatory Safety Pharmacology investigations into risk-known exercises.
authors.affiliation: Via dei Bacchettoni, LUCCA, Italy. iciliocavero@aol.com
authors.forename: Icilio
authors.initials: I
authors.lastname: Cavero
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D001702:Biopharmaceutics; D001711:Biotransformation; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology; D003198:Computer Simulation; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000592:standards; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007880:Legislation, Drug; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000592:standards; D012140:Respiratory Tract Diseases / Q000139:chemically induced / Q000453:epidemiology; D018570:Risk Assessment; D012449:Safety; D015027:Zebrafish
chemical_list: D004364:Pharmaceutical Preparations